Alvotech Total Liabilities
Alvotech total liabilities. Based on the latest financial reports, Alvotech (ALVO) has total liabilities worth Ikr1.59 Billion ISK (≈ $12.93 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See ALVO cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Alvotech (2020–2024)
Total liabilities of Alvotech from 2020 to 2024. This chart illustrates how Alvotech's total liabilities have evolved over time, based on quarterly financial data. Explore ALVO long-term investments to assets to see how much of total assets are deployed in long-term investments.
Alvotech Competitors by Total Liabilities
The table below lists competitors of Alvotech ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Blue Dart Express Limited
NSE:BLUEDART
|
India | Rs-17.77 Billion |
|
Arendals Fossekompani ASA
OL:AFK
|
Norway | Nkr3.18 Billion |
|
Chang Wah Electromaterials Inc
TW:8070
|
Taiwan | NT$17.92 Billion |
|
Sitronix Technology Corp
TW:8016
|
Taiwan | NT$7.93 Billion |
|
Hartalega Holdings Bhd
KLSE:5168
|
Malaysia | RM495.00 Million |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089
|
China | CN¥1.10 Billion |
|
Beijing Strong Biotechnologies Inc
SHE:300406
|
China | CN¥1.30 Billion |
|
Tompkins Financial Corporation
NYSE MKT:TMP
|
USA | $7.68 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Alvotech's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ALVO total assets.
Liquidity & Leverage Metrics
Alvotech Total Liabilities Ratios Explained
Alvotech total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -8.97 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alvotech's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alvotech (2020–2024)
The table below shows the annual total liabilities of Alvotech from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Ikr1.63 Billion ≈ $13.32 Million |
-13.20% |
| 2023-12-31 | Ikr1.88 Billion ≈ $15.35 Million |
+35.16% |
| 2022-12-31 | Ikr1.39 Billion ≈ $11.36 Million |
+89.87% |
| 2021-12-31 | Ikr733.59 Million ≈ $5.98 Million |
-45.32% |
| 2020-12-31 | Ikr1.34 Billion ≈ $10.94 Million |
-- |
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic art… Read more